Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

According to Stifel, the Meta partnership positions EssilorLuxottica at the forefront of the smart glasses revolution. The ...

Stifel raised the firm’s price target on New Fortress Energy (NFE) to $23 from $17 and keeps a Buy rating on the shares. The firm notes that on ...

Thursday, January 23, 2025, marks the release of a new report by Stifel analysts on the US transport sector. The report outlines a cautious perspective on the industry's future, noting that while 2024 ...

CEO Ron Kruszewski and Yahoo Finance Executive Editor Brian Sozzi at the 2025 World Economic Forum in Davos, Switzerland, to talk about the macro issues impacting the investment banking firm, ...

With capacity declines driving more freight market gains than demand in 2025, FedEx Freight’s spin-off and march to more ...

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market ...

Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates and artificial intelligence's impact on jobs.

Stifel raised the firm’s price target on Werner (WERN) to $35 from $30 and keeps a Hold rating on the shares. 2024 largely proved to be “the ...

Stifel analyst Brian Brophy raised the firm’s price target on Quanta Services (PWR) to $388 from $374 and keeps a Buy rating ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...